Covid-19 roundup: Controversy around colchicine percolates after study failure; AstraZeneca's meeting with EU was 'constructive,' but didn't solve much
A group of researchers at the Montreal Heart Institute has spelled out what they had called positive results suggesting that colchicine, an inexpensive oral anti-inflammatory drug commonly used to treat gout, could prevent Covid-19 complications in newly diagnosed patients.
The study failed its primary endpoint. But the latest scientific debate around treatments for the coronavirus is just beginning to brew.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.